久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Tessa Receives PRIME Designation from EMA for CD30 CAR-T Therapy americanpharmaceuticalreview
    January 27, 2021
    Tessa Therapeutics announced the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).
  • Tessa Therapeutics Appoints CCO contractpharma
    July 24, 2017
    Butler brings 20 years of pharma/biopharma experience across several therapeutic areas
PharmaSources Customer Service